非小细胞肺癌治疗方案的药物经济学评价综述

Review of Pharmacoeconomics Evaluation of Non-small Cell Lung Cancer

目的:本研究旨在对国内外非小细胞肺癌(NSCLC)治疗方案的药物经济学评价进行分析,发现国内评价中存在的不足。方法:检索CNKI、万方、Pubmed、EMbase等数据库,筛选出文章20篇,分析模型、成本、产出等要素。结果:国内评价模型大多采用决策树模型,不能反映非小细胞肺癌治疗的长期效果,成本的测算也仅考虑直接医疗成本,研究中大多选择有效率等,未能综合考虑产出。结论:在进行非小细胞肺癌的药物经济学评价时,Markov或半Markov是较为合理的模型选择,成本测算时以全社会的角度更为合理,质量调整生命年(QALYs)也是更加全面的产出指标。

Objective： To analyze Chinese and English literatures for pharmacoeconomics evaluations of non-small cell lung cancer （NSCLC） treatment patterns. Methods ：We searched literatures in CNKI, Wanfang, Pubmed, and EMbase, and selected 20 literatures, analyzed their model, cost and outcome. Results：Decision models are widely used in Chinese researches, but they can hardly show treat- ment effectiveness in the long term. Most studies only take into account direct medical cost and response rate, which have several limita- tions. Conclusion：Markov or semi-Markov is suggested in such research, cost in the perspective of the whole society is more advisable, and QALYs can better describe patients＇ outcome.